Open Accessibility Menu
Hide

Genitourinary (GU)

Study Name: Apolo

  • Cancer Stage: I-IV
  • Key Inclusion: GU
  • Description: A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies in People a with Urinary Tract or GU Cancer such as Bladder, Kidney, Testicular, Prostate, Penis, or Neuroendocrine Cancer.
  • Study Number: NIH Protocol 000302
  • NCT#: NCT04923178

Study Name: Modern

  • Cancer Stage: II-IV
  • Key Inclusion: muscle invasive urothelial, CT DNA +
  • Description: Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
  • Study Number: A032103
  • NCT#: NCT05987241

Study Name: ICONIC

  • Cancer Stage: IV
  • Key Inclusion: N/A
  • Description: Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
  • Study Number: A031702
  • NCT#: NCT03866382

Study Name: GAIN-BCG

  • Cancer Stage: Ta, high grade, Tis
  • Key Inclusion: within 120 days prior to randomization
  • Description: Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy (GAIN-BCG)
  • Study Number: A032303
  • NCT#: NCT07000084

Study Name: Novastar

  • Cancer Stage: NMIBC
  • Key Inclusion: N/A
  • Description: A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States (Nova-sTAR)
  • Study Number: 10000302
  • NCT#: NCT07309445

Study Name: EA8231

  • Cancer Stage: IV
  • Key Inclusion: Anti-PD(L)-1 Resistant Adv. Urothelial; Locally Adv/Metastatic
  • Description: A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
  • Study Number: EA8231
  • NCT#: NCT06524544

Study Name: rBCG EAP

  • Cancer Stage: NMBIC
  • Key Inclusion: N/A
  • Description: ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer
  • Study Number: ResQ132EX-NMIBC
  • NCT#: NCT06810141

For more information, call 240-566-4100

All Locations